Cyclacel Pharmaceuticals (NASDAQ:BGMS) Stock Falls 9.3% – Should You Sell?

Cyclacel Pharmaceuticals, Inc. (NASDAQ:BGMS – Get Free Report)’s stock price traded down 9.3% during trading on Tuesday. The company traded as low as $0.58 and last traded at $0.59. Approximately 22,055 shares were traded during mid-day trading, a decline of 3% from the average daily volume of 22,669 shares. The stock had previously closed at $0.6502.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Cyclacel Pharmaceuticals in a research note on Tuesday, October 27th. One equities research analyst has rated the stock with a Sell rating. According to data from MarketBeat, the stock has a consensus rating of “Sell”.

Read Our Latest Research Report on Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals Trading Down 9.3%

The stock has a fifty day simple moving average of $0.88 and a 200-day simple moving average of $0.93. The stock has a market cap of $3.91 million, a price-to-earnings ratio of -0.25 and a beta of -0.44.

Cyclacel Pharmaceuticals (NASDAQ:BGMS – Get Free Report) last announced its earnings results on Thursday, November 12th. The company reported ($0.07) earnings per share (EPS) for the quarter. The company had revenue of $0.45 million for the quarter. Cyclacel Pharmaceuticals had a negative return on equity of 24.24% and a negative net margin of 74.40%.

About Cyclacel Pharmaceuticals

(Get Free Report)

Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Its research has centered on compounds that target cell-cycle regulation and other processes involved in cancer-cell growth. The company’s investigational drug candidates have included fadraciclib, a cyclin-dependent kinase inhibitor, and sapacitabine, an oral nucleoside analogue. These candidates have been studied for potential use in hematologic cancers and solid tumors; they are not approved medicines.

Further Reading

Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.